• Increase
  • Decrease
  • Normal

Current Size: 100%

Ed Forum 2016 SGL

Leukaemia Foundation of Australia

 

 

The Leukaemia Foundation Education Session with Dr Steven Treon

Melbourne Convention and Exhibition Centre South Wharf Melbourne 3006

2:00-4:30 PM 15 November 2016

 

The Leukaemia Foundation has provided advance detail of the invitation for WMozzies to attend an education session with Dr Steven Treon at the Melbourne Convention and Exhibition Centre South Wharf Melbourne 3006.

This is a meeting for the Waldenström’s Macroglobulinemia community not to be missed.

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and an Attending Physician for the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

 

Importantly for WMozzies like me who are in the  INNOVATE ibrutinib clinical trial in Australia, Dr. Treon served as the principal investigator of the pivotal trial that supported the regulatory approval of ibrutinib by the U.S. FDA and European Medicines Agency for the treatment of WM. He has also been the principal investigator for other clinical trials that resulted in the adoption of many novel therapeutics and combination therapies for the treatment of WM.

 

Dr Treon will be joined at the meeting by Australian haematologists including Assoc. Professor Judith Trotman from the Concord Cancer Centre and is Principal Investigator on INNOVATE clinical trial in Sydney and is Principal Investigator of the WM patient WhiMSICAL Study.  

Dr. Treon’s research interests are focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of targeted therapeutics for this malignancy. Using whole genome sequencing, the Treon laboratory discovered the highly prevalent MYD88 L265P and CXCR4 WHIM mutations in WM. This permitted the development of diagnostic molecular testing and targeted treatments for WM. Dr. Treon served as the principal investigator of the pivotal trial that supported the regulatory approval of ibrutinib by the U.S. FDA and European Medicines Agency for the treatment of WM. He has also been the principal investigator for other clinical trials that resulted in the adoption of many novel therapeutics and combination therapies for the treatment of WM.

RSVPs for the meeting should be sent to Leukaemia Foundation, Tennille Lewin tlewin@leukaemia.org.au

Dr Treon was a keynote speaker at the WMozzies inaugural meeting in Sydney in 2005 organised by IWMF and WMozzies founder Gareth Evans

I look forward to seeing many WMozzies at this event of the decade for the Waldenström’s Macroglobulinemia community organised by the Leukaemia Foundation

Andrew Warden   30 Coasters Rtt  Coasters Retreat NSW 2108 Australia   Mobile 0408 303 718

Event Date: 
Tuesday, November 15, 2016
Location: 
1 Convention Centre Pl
South Wharf , VIC
Australia
Event Type: 
Section: